Literature DB >> 15711910

Long-term management of prolactinomas--use of long-acting dopamine agonists.

David M Cook1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15711910     DOI： 10.1007/s11154-005-5220-4

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  28 in total

1.  The macroprolactin problem.

Authors:  Janet A Schlechte
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

2.  Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays.

Authors:  Thomas P Smith; Abdulwahab M Suliman; Michael N Fahie-Wilson; T Joseph McKenna
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.

Authors:  E St-Jean; F Blain; R Comtois
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

4.  Oral contraceptives and pituitary adenomas.

Authors:  S J Wingrave; C R Kay; M P Vessey
Journal:  Br Med J       Date:  1980-03-08

5.  Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.

Authors:  H Leslie; C H Courtney; P M Bell; D R Hadden; D R McCance; P K Ellis; B Sheridan; A B Atkinson
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

6.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

Authors:  Annamaria Colao; Giovanni Vitale; Paolo Cappabianca; Francesco Briganti; Antonio Ciccarelli; Michele De Rosa; Stefano Zarrilli; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  The natural history of untreated microprolactinomas.

Authors:  D A Sisam; J P Sheehan; L R Sheeler
Journal:  Fertil Steril       Date:  1987-07       Impact factor: 7.329

8.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

9.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.

Authors:  Michele De Rosa; Stefano Zarrilli; Giovanni Vitale; Carolina Di Somma; Francesco Orio; Libuse Tauchmanova'; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245
View more
  1 in total

Review 1.  [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

Authors:  A Schäffler
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.